Metabolism and function of polyamines in cancer progression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sari, Ita Novita | - |
dc.contributor.author | Setiawan, Tania | - |
dc.contributor.author | Kim, Kwang Seock | - |
dc.contributor.author | Wijaya, Yoseph Toni | - |
dc.contributor.author | Cho, Kae Won | - |
dc.contributor.author | Kwon, Hyog Young | - |
dc.date.accessioned | 2021-10-05T04:41:12Z | - |
dc.date.available | 2021-10-05T04:41:12Z | - |
dc.date.issued | 2021-10-28 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.issn | 1872-7980 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19799 | - |
dc.description.abstract | Polyamines are essential for the proliferation, differentiation, and development of eukaryotes. They include spermine, spermidine, and the diamine precursor putrescine, and are low-molecular-weight, organic polycations with more than two amino groups. Their intracellular concentrations are strictly maintained within a specific physiological range through several regulatory mechanisms in normal cells. In contrast, polyamine metabolism is dysregulated in many neoplastic states, including cancer. In various types of cancer, polyamine levels are elevated, and crosstalk occurs between polyamine metabolism and oncogenic pathways, such as mTOR and RAS pathways. Thus, polyamines might have potential as therapeutic targets in the prevention and treatment of cancer. The molecular mechanisms linking polyamine metabolism to carcinogenesis must be unraveled to develop novel inhibitors of polyamine metabolism. This overview describes the nature of polyamines, their association with carcinogenesis, the development of polyamine inhibitors and their potential, and the findings of clinical trials. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Metabolism and function of polyamines in cancer progression | - |
dc.type | Article | - |
dc.publisher.location | 아일랜드 | - |
dc.identifier.doi | 10.1016/j.canlet.2021.06.020 | - |
dc.identifier.scopusid | 2-s2.0-85109201378 | - |
dc.identifier.wosid | 000689641200002 | - |
dc.identifier.bibliographicCitation | Cancer Letters, v.519, pp 91 - 104 | - |
dc.citation.title | Cancer Letters | - |
dc.citation.volume | 519 | - |
dc.citation.startPage | 91 | - |
dc.citation.endPage | 104 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | S-ADENOSYLMETHIONINE DECARBOXYLASE | - |
dc.subject.keywordPlus | TARGETING ORNITHINE-DECARBOXYLASE | - |
dc.subject.keywordPlus | PROGRAMMED CELL-DEATH | - |
dc.subject.keywordPlus | ALPHA-DIFLUOROMETHYLORNITHINE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | K-RAS | - |
dc.subject.keywordPlus | POSTRADIOTHERAPY CHEMOTHERAPY | - |
dc.subject.keywordPlus | POLYAMINOHYDROXAMIC ACIDS | - |
dc.subject.keywordPlus | IRREVERSIBLE INHIBITOR | - |
dc.subject.keywordPlus | PANCREATIC-CANCER | - |
dc.subject.keywordAuthor | Polyamine | - |
dc.subject.keywordAuthor | Metabolism | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.